Clinical trials: leukemia, open to volunteers
T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma
Universal 4SCAR7U Targeting CD7-positive Malignancies
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of universal CAR T cells based on 4SCAR7U design against CD7-positive hematological malignancies using CD7 specific universal CAR T cells.
- Conditions
- T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, Acute Myeloid Leukemia, NK Cell Lymphoma
- Trial name
- NCT05995028
- Testing
- Universal CD7-specific CAR gene-engineered T cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Relapsed/Refractory (R/R) Hematologic Malignancies, Acute Leukemia
A Study to Assess the Pharmacokinetics and Safety of Revumenib in Participants With Advanced Cancer and Hepatic or Renal Impairment
The primary purpose of this study is to characterize the pharmacokinetic (PK) parameters of revumenib and its major metabolite, N-deethyl revumenib (M1) after a single dose of revumenib in participants with severe liver or kidney…
- Conditions
- Relapsed/Refractory (R/R) Hematologic Malignancies, Acute Leukemia, Refractory Leukemia, Relapsed Leukemia
- Trial name
- NCT07923071
- Testing
- Revumenib
- Volunteers
- 18 people
- Sponsor
- Syndax Pharmaceuticals
T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma
Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of CAR T cell therapy against CD7-positive hematological malignancies using CD7 specific CAR T cells.
- Conditions
- T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, Acute Myeloid Leukemia, NK Cell Lymphoma
- Trial name
- NCT04033302
- Testing
- CD7-specific CAR gene-engineered T cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Leukemia, Myeloid, Acute
Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse
The goal of this clinical research study is to learn if azacitidine combined with Chidamide will help to control the disease in patients with high-risk AML after an allogeneic stem cell transplant.
- Trial name
- NCT05270200
- Testing
- Azacitidine, Chidamide
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhujiang Hospital
Chronic Myeloid Leukemia
Asciminib RMP Study
This study is a prospective, open-label, multi-center, non-comparative, observational study to assess safety and effectiveness of Asciminib in the real-world clinical setting in Korean Chronic myeloid leukemia (CML) patients.
- Trial name
- NCT05943522
- Testing
- Asciminib
- Where
- 17 sites in South Korea
- Volunteers
- 600 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Lymphocytic Leukemia, CLL
Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom
This is a retrospective observational research study to describe the characteristics and real-world clinical outcomes of patients with chronic lymphocytic leukaemia receiving acalabrutinib in the United Kingdom (the EPIC study).
- Trial name
- EPIC (NCT05557695)
- Testing
- Acalabrutinib
- Where
- 29 sites in United Kingdom
- Volunteers
- 287 people
- Sponsor
- AstraZeneca
Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse
Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML
The goal of this research study is to test if the combination of a new T cell therapy (dendritic cell (DC) / acute myeloid leukemia (AML) primed T cells), vaccine (DC/AML fusion vaccine) and standard of care decitabine and…
- Trial name
- NCT07374029
- Testing
- DC/AML Fusion Vaccine, T-Cell Therapy, Decitabine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- David Avigan
Acute Leukemia
Benefits of Formalized Care Support Program Following Acute Leukemia Diagnosis
The purpose of this study is to determine the impact on anxiety between patients with a period of care support following their announcement of an acute leukemia (AL) diagnosis and patients without this accompaniment.
- Trial name
- ANX-LA (NCT07499765)
- Testing
- care support program after diagnosis announcement
- Where
- France
- Volunteers
- 110 people
- Sponsor
- Centre Henri Becquerel
Relapsed/Refractory Plasma Cell Leukemia, Relapsed/Refractory Multiple Myeloma
A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia
A Clinical Study to Explore the Safety, Efficacy, and Cellular Metabolic Dynamics of CT0596 CAR-T Cell Injection in Patients With Relapsed/Refractory Multiple Myeloma and Plasma Cell Leukemia.
- Trial name
- NCT06730256
- Testing
- CAR-T cells Infusion chimeric antigen receptor T cells
- Where
- China
- Volunteers
- 24 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Philadelphia Positive Acute Lymphoblastic Leukemia
A Study of LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, BCR::ABL1-Positive Acute Lymphoblastic Leukemia (ALL)
The purpose of this research study is to see if a drug called LP-118 is safe and effective for treating adults with Philadelphia chromosome-positive (Ph+) B cell acute lymphoblastic leukemia (ALL), when given with ponatinib…
- Trial name
- NCT07614022
- Testing
- LP-118
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Wake Forest University Health Sciences
Leukemia, Acute Lymphoblastic
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
ALLTogether collects the experience of previously successful treatment of infants, children and young adults, with ALL from a number of well-renowned study groups into a new master protocol, which is both a comprehensive system…
- Trial name
- NCT04307576
- Testing
- Omitted Doxorubicin, Omitted Vincristine+Dexamethasone pulses, Inotuzumab Ozogamicin+Standard Maintenance Therapy
- Where
- 137 sites in Belgium, Denmark and 13 more
- Volunteers
- 6,430 people
- Sponsor
- Mats Heyman
B-cell Acute Lymphoblastic Leukemia
CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL
This study will evaluate the safety and tolerability of administering a novel bispecific CD19/CD22-directed CAR T cell product (CD19x22) for the treatment of relapsed or refractory pediatric B-ALL.
- Trial name
- NCT06559189
- Testing
- CD19x22 CAR T
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- University of Colorado, Denver
AML/MDS, Acute Myeloid Leukemia
Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML
This is a Phase 1 study investigating the safety and efficacy of Danvatirsen as a monotherapy followed by combination with Venetoclax in patients with relapsed/refractory myelodysplastic syndromes (MDS) or acute myeloid leukemia…
- Conditions
- AML/MDS, Acute Myeloid Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT05986240
- Testing
- Danvatirsen, Danvatirsen + Venetoclax
- Where
- 2 sites in United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Montefiore Medical Center
Acute Myeloid Leukemia, Acute Myeloid Leukemia With KMT2A Rearrangement
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
This phase Ib trial tests the safety, side effects, and best dose of SNDX-5613 when given in combination with the standard chemotherapy treatment (daunorubicin and cytarabine) in treating patients with newly diagnosed acute…
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia With KMT2A Rearrangement, Acute Myeloid Leukemia With NPM1 Mutation, Secondary Acute Myeloid Leukemia
- Trial name
- NCT05886049
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 23 sites in United States
- Volunteers
- 38 people
- Sponsor
- National Cancer Institute (NCI)
AML (Acute Myelogenous Leukemia, Relapsed Acute Myelogenous Leukemia
Clinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of WBC100 capsules in patients with relapsed or refractory acute myeloid leukemia (R/R AML).
- Conditions
- AML (Acute Myelogenous Leukemia, Relapsed Acute Myelogenous Leukemia, Refractory Acute Myeloid Leukemia, Hematologic Malignancy
- Trial name
- NCT07014449
- Testing
- WBC100 QD
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Hangzhou Weben Pharma Co., Ltd
Neurofibroma, Plexiform, Precursor Cell Lymphoblastic Leukemia-Lymphoma
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
Background: Some people with cancer have solid tumors. Others have refractory leukemia. This may not go away after treatment. Researchers want to see if a drug called TURALIO(R) can shrink tumors or stop them from growing.
- Conditions
- Neurofibroma, Plexiform, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Promyelocytic, Acute, Sarcoma
- Trial name
- NCT02390752
- Testing
- TURALIO(R)
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Myeloid Leukemia, Treatment-free Remission
Treatment Free Remission (TFR) in CML Patients （CML-CP）Study
Improving the quality of life and achieving Treatment-Free Remission(TFR) is a long-term goal of treatment in CML-CP patients, and deep molecular response (DMR) is necessary to achieve TFR.
- Trial name
- NCT05440747
- Testing
- TFR(Treatment-Free Remission)
- Volunteers
- 203 people
- Sponsor
- Guangdong Provincial People's Hospital
T-ALL/Lymphoma
Clinical Trial of CD5-targeted CAR-NK Therapy for Relapse/Refractory T-Cell Hematologic Malignancies
This is a clincal trial initiated by investigator to evaluate the safety and efficacy of anti-CD5 CAR-NK in the treatment of patients with relapsed/refractory T-Cell hematologic malignancies.
- Trial name
- NCT06909474
- Testing
- Anti-CD5 CAR NK cells
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Adult Acute Myeloid Leukemia
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
This is a multi-center, randomized, double-blinded, placebo controlled trial.
- Trial name
- MO-TRANS (NCT05429632)
- Testing
- mocravimod
- Where
- 111 sites in United States, Argentina and 12 more
- Volunteers
- 366 people
- Sponsor
- Priothera SAS
Cancer, Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma)
Immune Adverse Events Registry in Onco-Hematologic Patients Treated With Immunotherapy
Immunotherapy is a therapeutic strategy aimed at inducing the immune system to identify and combat cancer cells and, alongside the evident clinical success observed in many patients, a specific toxicity profile has emerged…
- Conditions
- Cancer, Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma), Cancer (Solid Tumors), Cancer (With or Without Metastasis)
- Trial name
- MITOX (NCT07198958)
- Volunteers
- 500 people
- Sponsor
- IRCCS San Raffaele
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.